Triple Negative Breast Cancer News and Research

RSS

Researchers test genomic sequencing for women with triple negative breast cancer

Indiana University cancer researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for those with an aggressive form of breast cancer.

15 May 2014

EntreMed reports net loss of $1.5M in first quarter 2014

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014.

15 May 2014

Scientists find new way to predict response to platinum-based chemotherapy in women with triple-negative breast cancer

Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer.

15 May 2014

Study links triple-negative breast cancer to ethnicity, independent of socioeconomics

An analysis of a large nationwide dataset finds that regardless of their socioeconomic status, black women were nearly twice as likely as white women to be diagnosed with triple-negative (TN) breast cancer, a subtype that has a poorer prognosis.

14 May 2014

Tumor-suppressing protein acts as dimmer switch to dial down gene expression

A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014.

11 Apr 2014

Susan G. Komen announces new grants to seven breast cancer organizations

Susan G. Komen today announced more than $1.89 million in new grants to seven breast cancer organizations serving the National Capital Region. The announcement came during the Susan G. Komen Global Race for the Cure Media Kickoff Event and Survivor Roundtable marking the official start of activities leading up to the 25th Global Race for the Cure May 10 on the National Mall.

3 Apr 2014

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 (Kadcyla).

2 Apr 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, a particularly deadly strain that often has few treatment options. Their research, published in this week's Nature, suggests that targeting the gene may be a new approach to treating the disease.

25 Mar 2014

Researchers use "big data" analytics to predict triple-negative breast cancer and other cancers with 95% accuracy

Researchers at Case Western Reserve University and colleagues used "big data" analytics to predict if a patient is suffering from aggressive triple-negative breast cancer, slower-moving cancers or non-cancerous lesions with 95 percent accuracy.

19 Mar 2014

Blocking myoferlin gene can reduce breast cancer cell migration

New research suggests that a protein only recently linked to cancer has a significant effect on the risk that breast cancer will spread, and that lowering the protein's level in cell cultures and mice reduces chances for the disease to extend beyond the initial tumor.

4 Mar 2014

New research points to potential target for treating triple negative breast cancer

New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease.

17 Feb 2014

EMT program in human cells may provide an effective approach for treating triple-negative breast cancer

A new study led by University of Kentucky Markey Cancer Center researcher Peter Zhou shows that targeting Twist, a nuclear protein that is an accelerant of the epithelial-mesenchymal transition (EMT) program in human cells, may provide an effective approach for treating triple-negative breast cancer.

12 Feb 2014

New surgical guidelines have potential to reduce unnecessary breast surgeries, improve patient outcomes

New surgical guidelines announced today by the Society of Surgical Oncology and the American Society for Radiation Oncology have the potential to significantly reduce unnecessary breast surgeries, improve patient outcomes and empower women to make important decisions with their doctors about their breast cancer treatment.

10 Feb 2014

Young women smokers may have increased risk of developing common type of breast cancer

Young women who smoke and have been smoking a pack a day for a decade or more have a significantly increased risk of developing the most common type of breast cancer.

10 Feb 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

Scientists discover potential cure for triple negative breast cancer

Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer." In laboratory experiments involving human cancer cells, scientists used a virus similar to the one that helped eradicate smallpox to coax cancer cells to produce a protein which makes them susceptible to radioactive iodine.

31 Jan 2014

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.

30 Jan 2014

Study shows melatonin hormone may inhibit tumor growth and cell production

An early stage study shows melatonin - a hormone that regulates the body's sleep and awake cycles - may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of S-o Paulo.

28 Jan 2014

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years.

28 Jan 2014

Triple Negative Breast Cancer News and Research

Researchers test genomic sequencing for women with triple negative breast cancer

EntreMed reports net loss of $1.5M in first quarter 2014

Scientists find new way to predict response to platinum-based chemotherapy in women with triple-negative breast cancer

Study links triple-negative breast cancer to ethnicity, independent of socioeconomics

Tumor-suppressing protein acts as dimmer switch to dial down gene expression

Susan G. Komen announces new grants to seven breast cancer organizations

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

Researchers use "big data" analytics to predict triple-negative breast cancer and other cancers with 95% accuracy

Blocking myoferlin gene can reduce breast cancer cell migration

New research points to potential target for treating triple negative breast cancer

EMT program in human cells may provide an effective approach for treating triple-negative breast cancer

New surgical guidelines have potential to reduce unnecessary breast surgeries, improve patient outcomes

Young women smokers may have increased risk of developing common type of breast cancer

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Scientists discover potential cure for triple negative breast cancer

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

Study shows melatonin hormone may inhibit tumor growth and cell production

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News